NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis $19.74 +1.48 (+8.07%) As of 02:44 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About PROCEPT BioRobotics Stock (NASDAQ:PRCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PROCEPT BioRobotics alerts:Sign Up Key Stats Today's Range$18.23▼$19.9450-Day Range$17.02▼$22.7652-Week Range$16.67▼$38.11Volume608,712 shsAverage Volume1.52 million shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$25.50Consensus RatingHold Company Overview PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures. Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue. The system is intended to support a consistent, anatomically guided procedure while preserving surrounding tissue and structures. PROCEPT has also developed software and related technologies to support treatment planning and delivery. Founded in 2007, PROCEPT BioRobotics received U.S. Food and Drug Administration clearance for its AquaBeam system in 2017. The company serves hospitals, health systems and urology practices in the United States and has expanded commercialization internationally, including in select European and other global markets. Its leadership has included President and Chief Executive Officer Reza Malekzadeh.AI Generated. May Contain Errors. Read More PROCEPT BioRobotics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScorePRCT MarketRank™: 3.66391917043 of 5 starsPROCEPT BioRobotics scored higher than 73% of companies evaluated by MarketBeat, and ranked 178th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingPROCEPT BioRobotics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 strong buy ratings, 2 buy ratings, 9 hold ratings, and 2 sell ratings.Upside PotentialPROCEPT BioRobotics has a consensus price target of $25.50, representing about 31.9% upside from its current price of $19.34.Amount of Analyst CoveragePROCEPT BioRobotics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PROCEPT BioRobotics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.67) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -9.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -9.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.51% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 5.32.Change versus previous monthShort interest in PROCEPT BioRobotics has recently decreased by 0.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.41 News SentimentPROCEPT BioRobotics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PROCEPT BioRobotics this week, compared to 8 articles on an average week.Search InterestOnly 3 people have searched for PRCT on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows3 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $476,464.00 in company stock, which represents 0.0430% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have bought 2,180.51% more of their company's stock than they have sold. Specifically, they have bought $498,315.00 in company stock and sold $21,851.00 in company stock.Percentage Held by Insiders4.00% of the stock of PROCEPT BioRobotics is held by insiders.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRCT Stock News HeadlinesPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Stock Has Average Price Target of $25.50 According to AnalystsOctober 20 at 3:59 AM | americanbankingnews.comPROCEPT BioRobotics Corp (PRCT) Shares Surge 4.0% -- What GF Score of 71 Tells InvestorsOctober 19 at 10:00 PM | gurufocus.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 22 at 1:00 AM | Weiss Ratings (Ad)PROCEPT BioRobotics (NASDAQ:PRCT) vs. Rockwell Medical (NASDAQ:RMTI) Financial SurveyOctober 17, 2026 | americanbankingnews.comLeerink Partners Sticks to Their Hold Rating for PROCEPT BioRobotics (PRCT)October 14, 2026 | theglobeandmail.comBarclays initiates coverage of PROCEPT BioRobotics at overweightOctober 12, 2026 | msn.comPROCEPT BioRobotics Corporation to Report Third Quarter 2026 Financial Results on November 4, 2026October 12, 2026 | quiverquant.comQPROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026October 12, 2026 | globenewswire.comSee More Headlines PRCT Stock Analysis - Frequently Asked Questions How have PRCT shares performed this year? PROCEPT BioRobotics' stock was trading at $31.46 on January 1st, 2026. Since then, PRCT shares have decreased by 38.5% and is now trading at $19.3390. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Corporation (NASDAQ:PRCT) issued its earnings results on Tuesday, August, 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01. The firm's revenue for the quarter was up 19.3% on a year-over-year basis. Read the conference call transcript. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $151 million in an initial public offering (IPO) on Tuesday, September 14th 2021. The company issued 6,556,000 shares at $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' top institutional shareholders include Frank Rimerman Advisors LLC (0.21%), Pinnacle Associates Ltd. (0.17%), KRS Capital Management LLC (0.08%) and IFP Advisors Inc (0.02%). Insiders that own company stock include Frederic H Moll, Antal Rohit Desai, Kevin Waters, Reza Zadno, Alaleh Nouri, Morgan Colby Wood, Barry L Templin, Hisham Shiblaq and Larry L Wood. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PROCEPT BioRobotics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PROCEPT BioRobotics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Oklo (OKLO), Super Micro Computer (SMCI), Palantir Technologies (PLTR), Rocket Lab (RKLB) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings8/04/2026Today10/22/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (18m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PRCT's financial health is in the Red zone, according to TradeSmith. PRCT has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PRCT CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees888Year Founded2009Price Target and Rating Average Price Target for PROCEPT BioRobotics$25.50 High Price Target$51.00 Low Price Target$19.00 Potential Upside/Downside+28.6%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.57 million Net Margins-32.53% Pretax Margin-32.49% Return on Equity-30.62% Return on Assets-22.10% Debt Debt-to-Equity Ratio0.15 Current Ratio6.55 Quick Ratio5.35 Sales & Book Value Annual Sales$337.34 million Price / Sales3.37 Cash FlowN/A Price / Cash FlowN/A Book Value$6.55 per share Price / Book3.03Miscellaneous Outstanding Shares57,274,000Free Float54,983,000Market Cap$1.14 billion OptionableOptionable Beta0.92 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PRCT) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump's bank just got approvedLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
